ICO to make a corporate presentation at small cap conference VANCOUVER, Nov. 21, 2013 /CNW/ - iCo Therapeutics Inc. (TSXV: ICO), today announced that Management will
be presenting at the sixth annual LD MICRO Conference. A corporate
presentation, highlighting the Company's Phase 2 iDEAL Study for
diabetic macular edema (DME), will take place at 12:30 pm EST,
Wednesday December 4th, 2013 at the Luxe Sunset Boulevard Hotel in Los
Angeles.
LD MICRO is a by-invitation only event focusing on finding undervalued
companies in the micro-cap space. The LD MICRO conference has steadily
grown each year, and is expecting over 400 investors to see and meet
with approximately 150 small and micro-cap companies at its 2013
conference.
About LD MICRO
LD MICRO is a by-invitation-only newsletter firm that focuses on finding
undervalued companies in the micro-cap space. Since 2002, the firm has
published an annual list of recommended stocks, as well as
comprehensive reports on select companies throughout the year. The firm
also hosts the LD MICRO Micro-Cap Growth Conference for investors in
December of each year. LD MICRO concentrates on finding, researching
and investing in companies that are overlooked by most institutional
investors. It is a non-registered investment advisor. For more
information visit www.ldmicro.com.
About iCo Therapeutics
iCo Therapeutics in-licenses and redefines existing drug candidates or
generics by employing reformulation and delivery technologies for new
or expanded use indications. The company has exclusive worldwide rights
to two drug candidates - iCo-007 for Diabetic Macular Edema (DME) and
iCo-008 for other sight-threatening diseases. iCo-007 is in Phase 2
clinical studies for DME. With Phase 2 clinical history, iCo-008 is
targeted for the treatment of keratoconjunctivitis and wet age-related
macular degeneration. In addition, iCo holds worldwide rights to an
oral drug delivery platform. The first platform candidate is the Oral
Amp B Delivery system, utilizing a known anti-fungal drug to treat
life-threatening infectious diseases. iCo trades on the TSX Venture
Exchange under the symbol "ICO". For more information, visit the
Company website at: www.icotherapeutics.com.
No regulatory authority has approved or disapproved the content of this
release. The TSX Venture Exchange does not accept responsibility for
the adequacy or accuracy of this release.
Forward Looking Statements
Certain statements included in this press release may be considered
forward-looking statements" within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by words such as:
"anticipate," "intend," "plan," "goal," "seek," "believe," "project,"
"estimate," "expect," "strategy," "future," "likely," "may," "should,"
"will," and similar references to future periods. Such statements
involve known and unknown risks, uncertainties and other factors that
may cause actual results, performance or achievements to be materially
different from those implied by such statements, and therefore these
statements should not be read as guarantees of future performance or
results. All forward-looking statements are based on iCo's current
beliefs as well as assumptions made by and information currently
available to iCo and relate to, among other things, anticipated
financial performance, business prospects, strategies, regulatory
developments, market acceptance and future commitments. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which are based only on information currently available to
iCo and speak only as of the date of this press release. Due to risks
and uncertainties, including the risks and uncertainties identified by
iCo in its public securities filings and on its website, actual events
may differ materially from current expectations. iCo disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise.
SOURCE: iCo Therapeutics Inc.
For further information:
Mr. John Meekison, CFO iCo Therapeutics 604-602-9414 x 224 meekison@icotherapeutics.com
Michael Moore, Investor Relations TMX Equicom 858-886-7813 mmoore@tmxequicom.com
----------------------------------------------------
Thank you for choosing TD Waterhouse. At TD Waterhouse, we are committed to providing you with the information, tools and resources you need to stay on top of the markets and invest with confidence.
To change your alert settings or to unsubscribe from the alerts service, please login to WebBroker.
TD Waterhouse Canada Inc. is a subsidiary of The Toronto-Dominion Bank. TD Waterhouse Canada Inc. - Member of the Canadian Investor Protection Fund. These products and/or services are only offered in jurisdictions where they may be lawfully offered for sale.
----------------------------------------------------
(c) 2013 CTVglobemedia Publishing Inc. All rights reserved.